Levetiracetam resistance: Synaptic signatures & corresponding promoter SNPs in epileptic hippocampi

Neurobiology of Disease

Volumn 60, Issue , 2013, Pages 115-125

  Grimminger, Tanja ^a   Pernhorst, Katharina ^a   Surges, Rainer ^a   Niehusmann, Pitt ^a   Priebe, Lutz ^a   von Lehe, Marec ^a   Hoffmann, Per ^a,b,c   Cichon, Sven ^a,b,c   Schoch, Susanne ^a   Becker, Albert J ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

A priori non responders; Luciferase; PIGP; Presynapse; Promoter variants

Indexed keywords

ETIRACETAM; MESSENGER RNA; TRANSCRIPTOME;

ALLELE; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE; GENE ACTIVATION; GENE CLUSTER; GENE EXPRESSION; GENE FREQUENCY; GENETIC SCREENING; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; LBP 1 GENE; MAJOR CLINICAL STUDY; PIGP GENE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TEMPORAL LOBE EPILEPSY; TRANSCRIPTOMICS; WNT SIGNALING PATHWAY;

A PRIORI NON-RESPONDERS; LUCIFERASE; PIGP; PRESYNAPSE; PROMOTER VARIANTS;

ADOLESCENT; ADULT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; EPILEPSY; FEMALE; HEXOSYLTRANSFERASES; HIPPOCAMPUS; HUMANS; INFANT; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PIRACETAM; POLYMORPHISM, SINGLE NUCLEOTIDE; PRESYNAPTIC TERMINALS; PROMOTER REGIONS, GENETIC; YOUNG ADULT;

EID: 84884728560     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.08.015     Document Type: Article

References (39)

1. Baldelli P., Fassio A., Valtorta F., Benfenati F. Lack of synapsin I reduces the readily releasable pool of synaptic vesicles at central inhibitory synapses. J. Neurosci. 2007, 27:13520-13531.
2. Banerjee D., Nandagopal K. Potential interaction between the GARS-AIRS-GART gene and CP2/LBP-1c/LSF transcription factor in Down syndrome-related Alzheimer disease. Cell. Mol. Neurobiol. 2007, 27:1117-1126.
3. Becker A.J., Pitsch J., Sochivko D., Opitz T., Staniek M., Chen C.C., et al. Transcriptional upregulation of Cav3.2 mediates epileptogenesis in the pilocarpine model of epilepsy. J. Neurosci. 2008, 28:13341-13353.
4. Berg A.T. The natural history of mesial temporal lobe epilepsy. Curr. Opin. Neurol. 2008, 21:173-178.
5. Blümcke I., Pauli E., Clusmann H., Schramm J., Becker A., Elger C., et al. A new clinico-pathological classification system for mesial temporal sclerosis. Acta Neuropathol. 2007, 113:235-244.
6. Cabrera M., Langemeyer L., Mari M., Rethmeier R., Orban I., Perz A., et al. Phosphorylation of a membrane curvature-sensing motif switches function of the HOPS subunit Vps41 in membrane tethering. J. Cell Biol. 2010, 191:845-859.
7. Chen Z.F., Kamiryo T., Henson S.L., Yamamoto H., Bertram E.H., Schottler F., et al. Anticonvulsant effects of gamma surgery in a model of chronic spontaneous limbic epilepsy in rats. J. Neurosurg. 2001, 94:270-280.
8. de Groot M., Toering S.T., Boer K., Spliet W.G., Heimans J.J., Aronica E., et al. Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex. Neuro Oncol. 2010, 12:265-273.
9. de Groot M., Aronica E., Heimans J.J., Reijneveld J.C. Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma. Neurology 2011, 77:532-539.
10. Dibbens L.M., Hodgson B.L., Helbig K.L., Oliver K.L., Mulley J.C., Berkovic S.F., et al. Rare protein sequence variation in SV2A gene does not affect response to levetiracetam. Epilepsy Res. 2012, 101:277-279.
11. Hall A.C., Lucas F.R., Salinas P.C. Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling. Cell 2000, 100:525-535.
12. Haucke V., Wenk M.R., Chapman E.R., Farsad K., De Camilli P. Dual interaction of synaptotagmin with mu2- and alpha-adaptin facilitates clathrin-coated pit nucleation. EMBO J. 2000, 19:6011-6019.
13. Heinemann U., Kann O., Remy S., Beck H. Novel mechanisms underlying drug resistance in temporal lobe epilepsy. Adv. Neurol. 2006, 97:85-95.
14. Hennessy M.J., Elwes R.D., Binnie C.D., Polkey C.E. Failed surgery for epilepsy. A study of persistence and recurrence of seizures following temporal resection. Brain 2000, 123(Pt 12):2445-2466.
15. Janz R., Goda Y., Geppert M., Missler M., Sudhof T.C. SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron 1999, 24:1003-1016.
16. Kaminski R.M., Gillard M., Leclercq K., Hanon E., Lorent G., Dassesse D., et al. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia 2009, 50:1729-1740.
17. Kral T., Clusmann H., Urbach J., Schramm J., Elger C.E., Kurthen M., et al. Preoperative evaluation for epilepsy surgery (Bonn Algorithm). Zentralbl. Neurochir. 2002, 63:106-110.
18. Kwan P., Arzimanoglou A., Berg A.T., Brodie M.J., Allen Hauser W., Mathern G., Moshé S.L., Perucca E., Wiebe S., French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010, 51(6):1069-1077. (Jun).
19. Lee G.H., Kim B.M., Kang J.K., Lee S.A. Loss of the initial efficacy of levetiracetam in patients with refractory epilepsy. Seizure 2013, 22:185-188.
20. Luna-Tortos C., Fedrowitz M., Löscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 2008, 55:1364-1375.
21. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:9861-9866.
22. Lynch J.M., Tate S.K., Kinirons P., Weale M.E., Cavalleri G.L., Depondt C., et al. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy. Epilepsy Res. 2009, 83:44-51.
23. Mbizvo G.K., Dixon P., Hutton J.L., Marson A.G. Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane review. Cochrane Database Syst. Rev. 2012, 9:CD001901.
24. Meehan A.L., Yang X., Yuan L.L., Rothman S.M. Levetiracetam has an activity-dependent effect on inhibitory transmission. Epilepsia 2012, 53:469-476.
25. Nowack A., Yao J., Custer K.L., Bajjalieh S.M. SV2 regulates neurotransmitter release via multiple mechanisms. Am. J. Physiol. Cell Physiol. 2010, 299:C960-C967.
26. Nowack A., Malarkey E.B., Yao J., Bleckert A., Hill J., Bajjalieh S.M. Levetiracetam reverses synaptic deficits produced by overexpression of SV2A. PLoS One 2011, 6:e29560.
27. Pernhorst K., Raabe A., Niehusmann P., van Loo K.M., Grote A., Hoffmann P., et al. Promoter variants determine gamma-aminobutyric acid homeostasis-related gene transcription in human epileptic hippocampi. J. Neuropathol. Exp. Neurol. 2011, 70:1080-1088.
28. Remy S., Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 2006, 129:18-35.
29. Remy S., Gabriel S., Urban B.W., Dietrich D., Lehmann T.N., Elger C.E., et al. A novel mechanism underlying drug resistance in chronic epilepsy. Ann. Neurol. 2003, 53:469-479.
30. Schmidt D., Löscher W. New developments in antiepileptic drug resistance: an integrative view. Epilepsy Curr. 2009, 9:47-52.
31. Schoch S., Gundelfinger E.D. Molecular organization of the presynaptic active zone. Cell Tissue Res. 2006, 326:379-391.
32. Shao M., Liu Z.Z., Wang C.D., Li H.Y., Carron C., Zhang H.W., et al. Down syndrome critical region protein 5 regulates membrane localization of Wnt receptors, dishevelled stability and convergent extension in vertebrate embryos. Development 2009, 136:2121-2131.
33. Surges R., Volynski K.E., Walker M.C. Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited. Ther. Adv. Neurol. Disord. 2008, 1:13-24.
34. Tanaka M., Bailey J.N., Bai D., Ishikawa-Brush Y., Delgado-Escueta A.V., Olsen R.W. Effects on promoter activity of common SNPs in 5' region of GABRB3 exon 1A. Epilepsia 2012, 53:1450-1456.
35. Voglmaier S.M., Kam K., Yang H., Fortin D.L., Hua Z., Nicoll R.A., et al. Distinct endocytic pathways control the rate and extent of synaptic vesicle protein recycling. Neuron 2006, 51:71-84.
36. Winden K.D., Karsten S.L., Bragin A., Kudo L.C., Gehman L., Ruidera J., et al. A systems level, functional genomics analysis of chronic epilepsy. PLoS One 2011, 6:e20763.
37. Winter C., tom Dieck S., Boeckers T.M., Bockmann J., Kampf U., Sanmarti-Vila L., et al. The presynaptic cytomatrix protein Bassoon: sequence and chromosomal localization of the human BSN gene. Genomics 1999, 57:389-397.
38. Wu Y., Matsui H., Tomizawa K. Amphiphysin I and regulation of synaptic vesicle endocytosis. Acta. Med. Okayama. 2009, 63:305-323.
39. Yao J., Nowack A., Kensel-Hammes P., Gardner R.G., Bajjalieh S.M. Cotrafficking of SV2 and synaptotagmin at the synapse. J. Neurosci. 2010, 30:5569-5578.